Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06950177 · ClinicalTrials.gov registry record · Phase 1
Pancoronavirus Vaccine Study in Healthy Adults
A Phase 1 study of SARS CoV 2 Infection and COVID-19 Respiratory Infection, sponsored by Duke University.
- Active
- Registry status
- Phase 1
- Development phase
- 51
- Enrollment target
- 1
- Study location
NCT06950177: Active Phase 1 study of SARS CoV 2 Infection and COVID-19 Respiratory Infection, sponsored by Duke University.
NCT06950177 is a Phase 1 study of SARS CoV 2 Infection and COVID-19 Respiratory Infection that is active but no longer recruiting, run by Duke University. The registered enrollment target is 51 participants, below the 4,186-participant average among 35 other SARS CoV 2 Infection trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06950177, a Phase 1 study of SARS CoV 2 Infection and COVID-19 Respiratory Infection, is active but no longer recruiting, sponsored by Duke University.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 51 participants
- Enrollment target
- 1
- Study location
Study Summary
Coronaviruses (CoVs) have caused the severe acute respiratory syndrome (SARS) outbreak, the Middle East Respiratory Syndrome (MERS) outbreak, and now the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic. Although there are several approved or authorized vaccines for SARS-CoV-2, there are currently no vaccines approved to prevent diseases caused by multiple different coronaviruses. Two countermeasures with promise for controlling coronavirus outbreaks are recombinant neutralizing antibodies and vaccines directed against the virus. Between these two countermeasures, the ultimate solution to control the current COVID-19 pandemic and future CoV outbreaks is a pancoronavirus vaccine. In particular, a vaccine that can induce broader protection and can prevent severe disease caused by current SARS-CoV-2 variants of concern would help mitigate significant morbidity and mortality following SARS-CoV-2 infection. Additionally, an optimal pancoronavirus vaccine would prevent severe disease from other SARS-related viruses in the genus of coronaviruses-betacoronavirus-that are responsible for past outbreaks or could cause the next major outbreak in humans. Such a broadly active coronavirus vaccine would be an impactful first step towards preventing all life-threatening coronavirus human disease. The proposed vaccine immunogen (Cov-RBD-scNP-001) is composed of an engineered receptor binding domain (RBD) of SARS-CoV-2 WA-1 covalently linked in vitro to the surface of a Helicobacter pylori ferritin protein nanoparticle (RBD-scNP). The RBD has been engineered at two sites to improve its expression. The protein nanoparticle is composed of 24 individual ferritin subunits each of which can have a SARS-CoV-2 WA-1 RBD attached to it via a nine amino acid linker. The protein nanoparticle will be delivered with 3M-052-AF adjuvant - a TLR 7/8 agonist.
Conditions Studied
Interventions
- BIOLOGICAL CoV-RBD-scNP-001 and 3M-052-AF
Study Locations (1)
North Carolina
- Duke University Health System - Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 51 participants |
| Start Date | 2025-07-08 |
| Est. Completion | 2026-08-30 |
| Phase | Phase 1 |
What the registry record for NCT06950177 still lists
NCT06950177 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 51 participants, a relatively small participant target, below the 4,186-participant average among 35 other SARS CoV 2 Infection trials with a reported enrollment target (99% lower).
The record links to 3 conditions, with SARS CoV 2 Infection appearing as the primary indexed condition, and to 1 intervention - of which CoV-RBD-scNP-001 and 3M-052-AF is the first listed.
NCT06950177 reports a single indexed study location in North Carolina.
Frequently Asked Questions
What is clinical trial NCT06950177 about?
NCT06950177 is a clinical study titled "Pancoronavirus Vaccine Study in Healthy Adults". Coronaviruses (CoVs) have caused the severe acute respiratory syndrome (SARS) outbreak, the Middle East Respiratory Syndrome (MERS) outbreak, and now the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic. Although there are several approved or authorized vaccines for SARS-CoV-2, ...
What is the current status of trial NCT06950177?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 51 participants. The study started on 2025-07-08. Estimated completion is 2026-08-30.
What conditions does trial NCT06950177 study?
This clinical trial studies the following conditions: SARS CoV 2 Infection, COVID-19 Respiratory Infection, COVID-19 Vaccine.
What interventions are being tested in trial NCT06950177?
The interventions under investigation include: CoV-RBD-scNP-001 and 3M-052-AF (BIOLOGICAL).
Who is sponsoring clinical trial NCT06950177?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06950177 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for SARS CoV 2 Infection
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06950177's enrollment target sits among peer trials
51 32nd of 35 higher than 4 of 35 other SARS CoV 2 Infection trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other SARS CoV 2 Infection trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
T Cell Therapy Opposing Novel COVID-19 Infection in Immunocompromised Patients
RECRUITING · Phase 1
-
A Phase 1/2A, Randomized Study of a T Follicular Helper (TFH)-Targeting Genetic Vaccine Strategy Designed to Induce Broad, Durable Immune Responses
RECRUITING · Phase 1
-
Human Convalescent Plasma for High Risk Children Exposed or Infected With SARS-CoV-2 (COVID-19)
COMPLETED · Phase 1
-
Exercise in Child Health
RECRUITING · NA
-
NIH RECOVER Tissue Pathology: Understanding the Long-Term Impact of COVID-19
RECRUITING
-
Cardiovascular Autonomic and Immune Mechanism of Post COVID-19 Tachycardia Syndrome
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02701153 · 51 participants · NA
Phase II Study of 5-Day Hypofractionated Preoperative Radiation Therapy for Soft Tissue Sarcomas: Expansion Cohort
- NCT03663790 · 51 participants · NA
Effects of Gait Retraining on Lower Extremity Biomechanics
- NCT03874052 · 51 participants · Phase 1
Ruxolitinib in Combination With Venetoclax With and Without Azacitidine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
- NCT04704661 · 51 participants · Phase 1
Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI